HomeCMVLF • OTCMKTS
add
Cellectis SA
Previous close
$4.40
Year range
$1.25 - $5.04
Market cap
237.52M USD
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 12.21M | -19.51% |
Operating expense | 29.56M | 14.37% |
Net income | -26.32M | -544.41% |
Net profit margin | -215.62 | -652.16% |
Earnings per share | -0.24 | -50.00% |
EBITDA | -14.23M | -90.95% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 208.66M | 45.66% |
Total assets | 324.72M | -15.34% |
Total liabilities | 248.82M | -1.46% |
Total equity | 75.90M | — |
Shares outstanding | 100.33M | — |
Price to book | 5.79 | — |
Return on assets | -12.99% | — |
Return on capital | -23.16% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -26.32M | -544.41% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
229
